利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.019 秒)

    Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parenteral administration and preparation process
    1.
    发明授权
    Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parenteral administration and preparation process 有权
    用于局部施用固体或半固体制剂和用于建议肠胃外给药和制备过程的延迟释放制剂的装置

    公开(公告)号：US07815928B2

    公开(公告)日：2010-10-19

    申请号：US11840271

    申请日：2007-08-17

    申请人： Roland Cherif Cheikh

    发明人： Roland Cherif Cheikh

    IPC分类号： A61F2/00

    CPC分类号： A61K9/0024 ,  A23L33/40 ,  A61D7/00 ,  A61K38/09 ,  A61K38/31 ,  A61M25/0084 ,  A61M37/0069

    摘要： A method for implanting or inserting a solid or semisolid formulation containing at least one active principle uses a device comprising one part set inside the body of the patient and which conditions the solid or semisolid form, brings these conditioning action to the deposit site, injects or inserts in this deposit site, and withdraws after injection or insertion, with one part remaining outside and activating the functions of the device. The invention also concerns a sustained-release solid formulation for parenteral administration comprising a homogeneous mixture of an active principle in non-dispersed state and of a biologically compatible and biodegradable excipient, in which the amount of active principle is at least 50% by weight.

    摘要翻译： 用于植入或插入含有至少一种活性成分的固体或半固体制剂的方法使用包含在患者体内的一部分组合并且固体或半固体形式的装置，将这些调理作用带到沉积部位，注射或 插入该存款点，并在注入或插入后退出，其中一部分保留在外部并激活设备的功能。 本发明还涉及用于肠胃外给药的持续释放固体制剂，其包含非分散状态的活性成分和生物相容性和生物降解性赋形剂的均匀混合物，其中活性成分的量为至少50重量％。

    Use of extracts of Ginkgo biloba for preparing a medicament intended to treat sarcopenia
    3.
    发明授权
    Use of extracts of Ginkgo biloba for preparing a medicament intended to treat sarcopenia 有权
    使用银杏提取物制备用于治疗肌肉减少症的药物

    公开(公告)号：US07138148B2

    公开(公告)日：2006-11-21

    申请号：US10481953

    申请日：2002-07-16

    申请人： Yves Christen

    发明人： Yves Christen

    IPC分类号： A61K36/16

    CPC分类号： A61K31/78 ,  Y10S514/907

    摘要： The invention concerns the use of Ginkgo biloba extracts, and in particular Ginkgo biloba extracts comprising 20 to 30% of flavoneglycosides, 2.5 to 4.5% in total of gingkolides A, B, C and J, 2 to 4% of bilobalide, less than 10% of proanthocyanidins and at least 10 ppm of alkylphenol type compounds, for preparing a medicine for treating sarcopenia.

    摘要翻译： 本发明涉及银杏叶提取物的使用，特别是银杏叶提取物，其包含20至30％的黄酮糖苷，2.5至4.5％的总皂甙A，B，C和J，2至4％的碧绿苷，小于10 ％的原花色素和至少10ppm的烷基酚型化合物，用于制备治疗肌肉减少症的药物。

    Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein
    7.
    发明申请
    Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein 审中-公开
    半胱氨酸衍生物用于制备旨在治疗异源三聚体G蛋白形成所致病态的药物

    公开(公告)号：US20060035899A1

    公开(公告)日：2006-02-16

    申请号：US11222601

    申请日：2005-09-09

    申请人： Gregoire Prevost ,  Marie-Odile Lonchampt ,  Thomas Gordon

    发明人： Gregoire Prevost ,  Marie-Odile Lonchampt ,  Thomas Gordon

    IPC分类号： A61K31/498

    CPC分类号： C07D487/04 ,  A61K31/223 ,  A61K31/498 ,  A61K31/4985 ,  C12N9/88 ,  Y02A50/471

    摘要： The invention relates to the use of cysteine derivatives for preparing a medicament intended to treat diseases which result from the formation of the heterotrimeric G protein. These diseases include in particular diseases linked to the following biological functions or disorders: smell, taste, perception of the light, neurotransmission, neurodegeneration, endocrine and exocrine gland functions, autocrine and paracrine regulation, arterial tension, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunological functions, diabetes, obesity, and benign :and malign proliferative diseases. Said cysteine derivatives include in particular: bis-1,1′-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazine disulphide (I), and bis-1,1′-7-(2-amino-1-oxo-3-thiopropyl-(2-(1-naphtyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1.2a]pyrazin-7-yl) disulphide (II).

    摘要翻译： 本发明涉及半胱氨酸衍生物用于制备旨在治疗由异三聚体G蛋白形成引起的疾病的药物的用途。 这些疾病特别包括与以下生物功能或障碍有关的疾病：气味，味觉，感觉，神经传递，神经变性，内分泌和外分泌腺功能，自分泌和旁分泌调节，动脉张力，胚胎发生，良性细胞增殖，肿瘤形成， 病毒感染，免疫功能，糖尿病，肥胖和良性：恶性增殖性疾病。 所述半胱氨酸衍生物特别包括：双-1,1' - [7-（2-氨基-1-氧代-3-硫丙基）-8-（环己基甲基）-2-（2-甲氧基苯基）-5,6,7 ，8-四氢咪唑并[1,2a]吡嗪二硫化物（I）和双-1,1'-7-（2-氨基-1-氧代-3-硫丙基 - （2-（1-萘基）-8-（2 - 甲基丙基）-5,6,7,8-四氢咪唑并[1.2a]吡嗪-7-基）二硫化物（II）。